|More on ASCO The ASCO Weekend Live Blog Recap|
Lisa K. asks, "Who were your winner and losers at ASCO this year?" Two easily identifiable winners: Bristol-Myers Squibb ( BMY) and Celgene ( CELG). The former grabbed the biggest headlines for the melanoma drug ipilimumab; the latter scored big with data establishing a new standard of care for multiple myeloma patients treated long-term with Revlimid as maintenance therapy.
Thank you, Wilford D.W. III! He emails , "Adam, when people are so negative in their comments towards you, they need to take their negativity somewhere else. The Sunesis Pharmaceuticals ( SNSS) and Delcath Systems people were particularly vitriolic in their negative comments. Frankly, if I were you, I would not publish any of the demeaning comments directed your way. These small-minded people apparently cannot tolerate any comment that does not extol the virtues of their darling stock. "People make money when they can objectively evaluate a company. Blind devotion to any company (or any cause for that matter) will cloud any objectivity towards that company. I thought your reporting was even-handed and fair. I appreciate the job you did at the